×

img Acces sibility Controls

Research Projects Banner

Research Projects

Development and evaluation of Human Chimeric Antigen Receptor-Macrophages (hCAR-Ma) in Human breast cancer organoid platform

Implementing Organization

Savitribai Phule Pune University
Principal Investigator
Dr. Tuli Dey
Savitribai Phule Pune University
CO-Principal Investigator
Dr. Shilpy Sharma
Savitribai Phule Pune University

About

Cancer is a highly dangerous non-communicable disease with high mortality and morbidity rates. Factors such as increased prevalence, delayed diagnosis, multi-drug resistance, exorbitant treatment costs, and tumor relapse make the situation worse. To combat this, the idea of weaponizing the host's immune system has emerged as a ray of hope. Several anti-cancer immune-therapies, including immune checkpoint blockade, cellular therapy, and cancer vaccines, are being developed. However, cell-based treatment remains the most successful, with the discovery of adoptive T cell therapy (ATC). Chimeric antigen receptor (CAR)-bearing T cells (CAR-T cells) have been successful for blood cancer treatment. However, CAR-T cells face problems in infiltrating solid tumors and limited fitness. A new concept has emerged to utilize CAR technology for solid tumors through macrophages. Screening of immunotherapeutics like CAR-T techniques relies on traditional cell culture systems and is validated in animal models. However, these models often fail to predict the correct outcomes in clinical trials. To solve this problem, engineered in vitro human-relevant models that mimic the critical components of tumor microenvironments can be used. The current project aims to produce human Chimeric Antigen Receptor-bearing macrophages (hCAR-Ma) for immunotherapeutic purposes and screen them through a human-relevant breast cancer model.
Funding Organization
Funding Organization
Science and Engineering Research Board (SERB), New Delhi
Anusandhan National Research Foundation (ANRF)
Quick Information
Area of Research
Life Sciences & Biotechnology
Start Year
2022
End Year
2025
Sanction Amount
₹ 28.62 L
Status
Completed
Output
No. of Research Paper
00
Technologies (If Any)
00
No. of PhD Produced
N/A
Startup (If Any)
00
No. of Patents
Filed :00
Grant :00
arrowtop